| Literature DB >> 34931119 |
Zahra Sadat Hashemi1, Mahboubeh Zarei2, Shaden M H Mubarak3, Anahita Hessami4, Maysam Mard-Soltani5, Bahman Khalesi6, Alireza Zakeri7, Mohammad Reza Rahbar2, Abolfazl Jahangiri8, Navid Pourzardosht9, Saeed Khalili7.
Abstract
The structural consequences of ongoing mutations on the SARS-CoV-2 spike-protein remains to be fully elucidated. These mutations could change the binding affinity between the virus and its target cell. Moreover, obtaining new mutations would also change the therapeutic efficacy of the designed drug candidates. To evaluate these consequences, 3D structure of a mutant spike protein was predicted and checked for stability, cavity sites, and residue depth. The docking analyses were performed between the 3D model of the mutated spike protein and the ACE2 protein and an engineered therapeutic ACE2 against COVID-19. The obtained results revealed that the N501Y substitution has altered the interaction orientation, augmented the number of interface bonds, and increased the affinity against the ACE2. On the other hand, the P681H mutation contributed to the increased cavity size and relatively higher residue depth. The binding affinity between the engineered therapeutic ACE2 and the mutant spike was significantly higher with a distinguished binding orientation. It could be concluded that the mutant spike protein increased the affinity, preserved the location, changed the orientation, and altered the interface amino acids of its interaction with both the ACE2 and its therapeutic engineered version. The obtained results corroborate the more aggressive nature of mutated SARS-CoV-2 due to their higher binding affinity. Moreover, designed ACe2-baased therapeutics would be still highly effective against covid-19, which could be the result of conserved nature of cellular ACE2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-021-10346-1.Entities:
Keywords: Lineage B.1.1.7.; Mutation; SARS-CoV-2; Spike protein; Structural analyses
Year: 2021 PMID: 34931119 PMCID: PMC8674523 DOI: 10.1007/s10989-021-10346-1
Source DB: PubMed Journal: Int J Pept Res Ther ISSN: 1573-3149 Impact factor: 1.931
Genomic information for EPI_ISL_601443
| Virus detail | Sample information | ||
|---|---|---|---|
| Virus name | hCoV-19/England/MILK-9E05B3/2020 | Collection date | 2020-09-20 |
| Accession ID | EPI_ISL_601443 | Location | Europe/United Kingdom/England |
| Variant | VUI202012/01 GR/501Y.V1 (B.1.1.7) | Host | Human |
| Passage details/history | Original | Sequencing technology | Illumina NovaSeq |
Fig. 1The RMSD and RMSF plots of the MD simulation. a Backbone RMSD concerning the initial structure of the monomeric form of mutant spike protein during the simulation time. B Cα RMSF of the monomeric form of mutant spike protein during the simulation time. C Rg versus time plot of the mutant spike protein during 50 ns MD simulation
Fig. 2Superimposition of spike glycoprotein before and after MD simulation. Protein structures are represented as cartoons. The gray ribbon is the mutant spike protein before MD simulation and white ribbons are the molecule after 50 ns MD simulation
Fig. 3The interaction orientation of ACE2 (in grey) with the wild type (a: magenta) and mutant (b: violet red) RBD of the spike proteins (Color figure online)
Fig. 4The interaction orientation of ACE2 wild type and mutant RBDs of the Spike protein and interface residues. The upper panel a shows the wild type RBD (plum) engaged in ACE2 (white). The lower panel b illustrates the engagement of mutant RBD (pink) in ACE2 (white). In both panels the interface residues are presented as ribbons the whole molecules are presented as transplant surfaces. Labels are including three letter code of amino acids, residue number, and the related chain. In both complexes RBDs are chain A and ACE2 are chain B. The different orientations of RBDs in complex with ACE2 are evidenced in the images (Color figure online)
Fig. 5The 2D plot of interactions between the ACE2 and wild type (a) and mutant (b) spike proteins (the amino acids with chain ID of B are from ACE2 and the amino acids with chain ID of A are from spike protein)
Fig. 6The illustration of residues of significant centrality scores in the interaction network. The nodes are representative of residues in the structure; triangles are chain A (RBD) and ellipses are chain B (ACE2). The sizes of nodes are proportional to the Z-scores of centrality. The color codes bellow each network define the Z-scores and edges. The left panel a is wildtype RBD and right panel b is the mutant RBD
Fig. 7The interaction orientation between the engineered ACE2 (light gray) and both wild type (a: magenta) and mutant (b: violet-red) spike proteins (Color figure online)